Maria Τektonidou/LinkedIn
Apr 2, 2026, 14:39
Maria Τektonidou: STAT1 as a Potential Therapeutic Target in Thrombotic Antiphospholipid Syndrome
Maria Τektonidou, Professor of Rheumatology at National and Kapodistrian University of Athens, shared a post on LinkedIn, about a recent article she and her colleagues co-authored, adding:
“Gene co-expression and drug-gene interaction analysis reveal STAT1 as a potential therapeutic target in thrombotic antiphospholipid syndrome”
Title: RNA sequencing-derived gene co-expression and drug-gene interaction analysis reveal STAT1 as a potential therapeutic target in thrombotic antiphospholipid syndrome
Authors: Michail Baltsiotis, Kleio-Maria Verrou, Petros P Sfikakis, Maria G Tektonidou
Read the Full Article on Frontiers in Immunology
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 12, 2026, 21:51Sam Botchey: Orthobiologics Are Advancing but the Evidence Must Keep Pace
-
Oct 12, 2026, 21:50Serum Vitamin D, Platelet Function, and Bleeding in Primary ITP – Platelets Journal
-
Oct 12, 2026, 21:30Nika Samadzadeh Tabrizi: Looking Forward to the PACeS Trial on Anticoagulation for POAF
-
Oct 12, 2026, 21:28Michael Megaly: Does Coronary Ectasia Affect Outcomes in Acute Coronary Syndromes?
-
Oct 12, 2026, 21:25Vitor Borin P. de Souza: Think Twice Before Anticoagulating an Isolated Subsegmental PE
-
Oct 12, 2026, 20:43Jazlyn A Selvasingh: Excited to Share Our Research at AAO-HNSF 2026 in Los Angeles
-
Oct 12, 2026, 20:31Natalia Kovtun: Higher Ferritin Cutoffs Now Define Iron Deficiency
-
Oct 12, 2026, 19:39Edward Loftus: Using Low-Dose Aspirin in Pregnant Women With IBD
-
Oct 12, 2026, 19:32Shruti Sachdeva: Strengthening the Fight against Anemia